Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Absci Corp(ABSI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ABSI
09/16/2026: ABSI (2-star) is currently NOT-A-BUY. Pass it for now.
Absci Corp is a biotechnology firm that utilizes generative AI to accelerate the discovery and design of novel therapeutic proteins. Its primary business strength lies in its integrated platform, which combines proprietary wet-lab data with deep learning to create more effective drug candidates. The main investment story centers on the company’s potential to revolutionize drug discovery and secure high-value partnerships with global pharmaceutical leaders. Investors should be aware of high execution risks, as the company remains pre-commercial and reliant on partner milestones. This stock may suit risk-tolerant growth investors, and key developments to monitor include successful clinical validation of partnered candidates and platform technological milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Absci offers high-growth potential in the AI-biology sector but carries significant execution and binary outcome risks. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunity during periods of favorable news regarding partnerships or technological breakthroughs. |
| Value investor | Weak fit | The company's lack of consistent profitability and reliance on future milestones makes it a poor fit for traditional value metrics. |
| Dividend investor | Weak fit | Absci pays no dividends and is focused exclusively on capital reinvestment for growth. |
| Low-risk investor | Weak fit | High volatility and early-stage business model risks make this unsuitable for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to news flow and broader market sentiment regarding the biotechnology sector. |
| Valuation risk | High | Valuations for pre-revenue biotech companies are often speculative and susceptible to sharp re-ratings. |
| AI competition risk | Medium / high | The company faces stiff competition from well-funded rivals developing similar AI-driven drug discovery platforms. |
| Business quality | Medium | While the platform technology is advanced, the company lacks a mature, recurring revenue stream. |
| Dividend income | Low / none | There is no income component to the investment thesis. |
| Execution risk | High | Success depends on the platform delivering actionable drug candidates that successfully pass clinical development. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 99.04% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/16/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.36B USD | Price to earnings Ratio - | 1Y Target Price 14.22 |
Price to earnings Ratio - | 1Y Target Price 14.22 | ||
Volume (30-day avg) 2.7M shares | Beta 2.44 | 52 Weeks Range 2.24 - 12.05 | Updated Date 09/16/2026 |
52 Weeks Range 2.24 - 12.05 | Updated Date 09/16/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Discovery Partnerships | Upfront payments, research milestone payments, and potential future royalties from partner-led development programs. | Revenue is tied to successfully meeting research goals for pharmaceutical partners rather than selling a retail product. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.19B | Price to Sales(TTM) 872.91 |
Enterprise Value 1.19B | Price to Sales(TTM) 872.91 | ||
Enterprise Value to Revenue 763 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 171.61M | Shares Floating 163.79M |
Shares Outstanding 171.61M | Shares Floating 163.79M | ||
Percent Insiders 11.84 | Percent Institutions 87.19 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Absci Corp
Exchange NASDAQ | Headquarters Vancouver, WA, United States | ||
IPO Launch date 2021-07-22 | Founder, CEO, President & Director Mr. Sean McClain | ||
Sector Healthcare | Industry Biotechnology | Full time employees 140 | Website https://www.absci.com |
Full time employees 140 | Website https://www.absci.com | ||
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.